Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: A Hellenic Co-operative Oncology Group (HeCOG) study
Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: A Hellenic Co-operative Oncology Group (HeCOG) study
复制标题
DOI：
10.1016/j.ygyno.2008.03.004
复制
发表时间：
2008-07-01
影响因子：
4.7
通讯作者：
Dimopoulos, Meletios-A.
中科院分区：
文献类型：
--
作者：
Papadimitriou, Christos A.;Bafaloukos, Dimitrios;Dimopoulos, Meletios-A.
目标。紫杉烷类、蒽环类和铂类化合物是转移性子宫内膜癌中活性最大的化疗药物。我们将紫杉醇、表柔比星和卡铂联合应用于转移性或复发性子宫内膜癌患者，以评估其活性并确定其毒性。63例连续患者在门诊基础上接受表柔比星50 mg/m(2)，随后紫杉醇150 mg/m(2)，静脉注射3小时。随后，患者在AUC为5时接受卡铂治疗。化疗在粒细胞集落刺激因子（G-CSF）支持下每3周重复一次，最多6个疗程。对56例符合条件的患者进行疗效评估。36例（63.2%）患者达到客观临床缓解（95% CI, 50.6-75.7%），其中14例（24.6%）完全缓解，22例（38.6%）部分缓解。中位缓解持续时间为7.9个月，所有患者的中位进展时间和生存时间分别为7.8和13.8个月。9例（15.5%）患者出现3级或4级中性粒细胞减少，但仅有3次出现中性粒细胞减少热。19%的患者出现2级或3级神经毒性。2例患者分别在第一个化疗周期后10天和14天死于心源性猝死，但这些死亡与治疗无关。紫杉醇、表柔比星和卡铂联合G-CSF支持在转移性或复发性子宫内膜癌患者中表现活跃。(C) 2008爱思唯尔公司版权所有。
Objective. Taxanes, anthracyclines, and platinum compounds represent the chemotherapeutic agents with the greatest activity in metastatic endometrial carcinoma. We administered the combination of paclitaxel, epirubicin and carboplatin to patients with metastatic or recurrent carcinoma of the endometrium to evaluate its activity and to define its toxicity.Methods. Sixty-three consecutive patients were treated on an outpatient basis with epirubicin 50 mg/m(2), followed by paclitaxel 150 mg/m(2), administered intravenously over a 3-h period. Subsequently, the patients received carboplatin at AUC of 5. The chemotherapy was repeated every 3 weeks with granulocyte colony-stimulating factor (G-CSF) support for a maximum of six courses.Results. Response was assessed among 56 eligible patients. Thirty-six (63.2%) patients achieved objective clinical response (95% CI, 50.6-75.7%) including 14 (24.6%) complete and 22 (38.6%) partial responses. The median duration of response was 7.9 months, and the median times to progression and survival for all patients were 7.8 and 13.8 months, respectively. Grade 3 or 4 neutropenia occurred in 9 (15.5%) patients but only 3 episodes of neutropenic fever were encountered. Grade 2 or 3 neurotoxicity was observed in 19% of patients. Two patients died of sudden cardiac death 10 and 14 days after the administration of the first chemotherapy cycle, respectively, but these deaths were not clearly treatment related.Conclusions. The combination of paclitaxel, epirubicin and carboplatin with G-CSF support appears active in patients with metastatic or recurrent carcinoma of the endometrium. (C) 2008 Elsevier Inc. All rights reserved.